AUTHORS
Meha Bhatt, MD, MSc, Nupur Krishnan, MD2, Shreya Gupta, BHSc3, David Agyare-Tabbi, BSc4, Ali Eshaghpour, MD5, Kerstin de Wit I, MD, MRCP, FRCEM, FRCPC6, Mark Crowther, MD MSc7, Siraj Mithoowani, MD, MHPE, FRCPC, FACP8
AFFILIATIONS
1 McMaster University, Hamilton, Ontario, Canada
2 McMaster University, Hamilton, Ontario, Canada
3 McMaster University, Hamilton, Ontario, Canada
4 McMaster University, Hamilton, Ontario, Canada
5 McMaster University, Hamilton, Ontario, Canada
6 Queen's University, Kingston, Ontario, Canada
7 McMaster University, Hamilton, Ontario, Canada
8 McMaster University, Hamilton, Ontario, Canada
ABSTRACT
Background: There is growing evidence supporting outpatient management for low-risk venous thromboembolism (VTE), but timely access to follow-up care is essential for patient safety. The American Heart Association 2026 guidelines recommend initial follow-up within 7 days following discharge to provide education to patients, address any barriers to anticoagulant therapy, and identify bleeding complications. Our aim was to evaluate the incidence of adverse clinical outcomes following emergency department (ED) discharge and identify risk factors associated with these outcomes at our institution, which routinely treats the large majority of VTE patients in the outpatient setting. We also assessed the time to follow-up in thrombosis clinic and frequency of anticoagulant prescription errors from the ED.
Methods: We conducted a retrospective cohort study of adult patients with a new diagnosis of acute VTE (deep vein thrombosis [DVT], pulmonary embolism [PE], or unusual site thrombosis) in the ED who were discharged with referral to an outpatient thrombosis clinic at tertiary care hospital in Hamilton, Canada from January 2018 to December 2024. For patients with more than one qualifying event, only the first VTE event and associated ED visit were included. We excluded patients with superficial VTE or those on therapeutic anticoagulation for other reasons. Outcomes included frequency of re-presentation to ED , hospital admission, recurrent VTE, major bleeding, clinically relevant non-major bleeding, and mortality in the 30-days following the index VTE. Data were analyzed descriptively. Data collection is ongoing, with final analysis expected for the ASH Annual Meeting. This study was approved by the Hamilton Integrated Research Ethics Board and funded by the Hamilton Health Sciences Resident Research Grant in Quality and Patient Safety.
Interim Results: This abstract reports data on a consecutive sample of 310 patients (total eligible patients, 925) who had been reviewed as of the submission date. The median age was 61 years [interquartile range (IQR) 46-73], and 145 (47%) patients were male. There were 181 (58%) patients with lower extremity DVT, 96 (31%) with PE, 9 (3%) with both lower extremity DVT and PE, 17 (5%) with upper extremity DVT, 5 (2%) with splanchnic vein thrombosis, and 3 (1%) with thrombosis in other locations. Clear provoking factors were identified for 93 (30%) events. A risk stratification score (i.e. PESI) was documented for 5 (4.6%) patients with PE in the ED notes. Phone advice from a Thrombosis consultant was documented for 114 (37%) of patients. Apixaban was the most prescribed anticoagulant on discharge (n=132, 42%), followed by rivaroxaban (n=97, 31%), and dalteparin (n=46, 15%). Of those who were started on direct oral anticoagulants, 8 of 132 (6%) patients on apixaban and 5 of 97 (5%) patients on rivaroxaban were not prescribed the Health Canada-recommended initial therapeutic dose. In the current cohort, 33 (10.6%) patients were lost to follow-up. Of the 277 patients who were seen in thrombosis clinic follow-up, the median time to follow-up in the thrombosis clinic was 5 days (IQR 1-15) and 118 (42%) patients were seen more than 7 days after the initial ED visit. In the 30 days after ED discharge, 53 patients (17%) re-presented to the ED, of whom 17 were admitted to the hospital. Reasons for presenting to ED included chest pain (n=12, 22%), leg swelling (n=9, 17%), bleeding (n=9, 17%), dyspnea (n=3, 6%), and other presenting complaints including causes unrelated to VTE (n=20, 38%). During this period, 20 patients (6%) developed clinically relevant non-major bleeding, 2 (0.6%) patients developed major bleeding, 4 (1%) had recurrent VTE, and there were no deaths. A multivariate analysis identifying risk factors associated with adverse outcomes is planned after data extraction is complete.
Conclusion: Outpatient thrombosis specialist follow-up exceeded the recommended one-week interval for over one third of patients. Short-term adverse events and ED re-presentations were common with outpatient management of acute VTE, despite overall low rates of recurrent VTE, major bleeding, and death. Future research should evaluate rapid follow-up after discharge with acute VTE and risk stratification of patients for follow-up planning, which may improve the safety and efficiency of outpatient VTE care.
DISCLOSURES
Meha Bhatt, MD, MSc: No relevant conflicts of interest to declare.